Indeed, TGF-β signaling mutations enhance EMT and, subsequently, tumorigenesis and metastases in the CRC-CMS4 subtype, while TGF-βRII mutation impairs EMT and provides a better prognosis [100]. The gene discussed is TGFB1; the disease is colorectal carcinoma.